Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.15, beating the estimate of USD -0.2.

EBIT: As of FY2026 Q1, the actual value is USD -5.154 M.

First Quarter 2026 Financial Results

Operating Expenses

Research and development expenses for the first quarter of 2026 were $2,669,779, compared to $2,436,998 for the first quarter of 2025, representing a $0.3 million increase primarily due to higher drug development costs for Halneuron® and increased salaries and personnel costs.General and administrative expenses for the first quarter of 2026 were $2,406,587, compared to $1,992,928 for the first quarter of 2025, with the $0.4 million increase mainly driven by higher salaries and related personnel costs, partially offset by a decrease in franchise fees.Total operating expenses for the first quarter of 2026 amounted to $5,076,366, up from $4,429,926 in the first quarter of 2025.

Net Loss and Per Share Data

Dogwood Therapeutics, Inc. reported a net loss attributable to common stockholders of -$4,986,614 for the first quarter of 2026, which is an improvement from -$12,181,614 for the first quarter of 2025.Basic and diluted net loss per share was -$0.15 for the first quarter of 2026, compared to -$8.45 for the first quarter of 2025.

Balance Sheet Data

As of March 31, 2026, cash and cash equivalents were $13,227,839, an increase from $6,524,744 as of December 31, 2025.Total assets stood at $95,207,871 on March 31, 2026, compared to $90,171,237 on December 31, 2025.Total liabilities decreased to $14,584,519 on March 31, 2026, from $15,274,370 on December 31, 2025.Total stockholders’ equity increased to $80,623,352 as of March 31, 2026, from $74,896,867 as of December 31, 2025.

Operational Metrics and Highlights

Dogwood Therapeutics, Inc. has enrolled 164 patients in its Halneuron® Phase 2b Chemotherapy Induced Neuropathic Pain (CINP) study.SP16 received Investigational New Drug (IND) approval from the FDA, with its study expected to begin enrolling in mid-2026 and fully funded by the National Cancer Institute.In January 2026, the company completed a financing of up to $26.9 million to advance Halneuron® through Phase 2b development, having received gross proceeds of $12.5 million.A Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets was announced, with a potential value of up to $100 million to Dogwood Therapeutics, Inc. and its current and former shareholders.

Outlook

Top-line results from the Halneuron® Phase 2b trial are anticipated in the fall of 2026, and the SP16 study is slated to commence enrollment in mid-2026.The company’s cash on hand of $13.2 million is projected to provide an operational runway into the fourth quarter of 2026.